Single Cell Technology (SCT) has pioneered a better way to identify and optimize antibodies. After several pharma contracts, SCT is poised to capitalize off its own technology to identify and commercialize both therapeutic and diagnostic antibodies. The company has a strong intellectual portfolio both in the United States and worldwide. SCT has licensed its technology for use in specific areas and anticipates additional partnerships in the future.In addition, SCT performs contract services for pharmaceutical and bio-pharmaceutical companies interested in the antibody repertoire of immune responses.
SCT’s platform combines micro-fabrication, next generation DNA sequencing (NGS), molecular biology, mechanical engineering, and bioinformatics together with patents and trade secrets.